This keeps blood sugar and energy more even
Landmark cardiovascular outcome trials (CVOTs) provided the first consistent signals of renal benefit with GLP-1RAs, largely driven by exploratory composite kidney endpoints and reductions in new or worsening albuminuria (e.g., LEADER, REWIND, SUSTAIN-6, EXSCEL, and ELIXA
Many researchers prefer the 10 mg/mL concentration for lower doses and switch to 20 mg/mL once they pass 7.5 mg weekly
Ordinary treatment over a length of weeks or months will yield greater effective effects compared to sporadic periods
Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
A benchmark, expand, and calibration (BenchExCal) trial emulation approach for using real-world evidence to support indication expansions: design and process for a planned empirical evaluation